Cerevel Therapeutics Hldg
(NASDAQ:CERE)
$41.99
-0.11[-0.26%]
At close: Apr 23
$41.99
0[0.00%]
After Hours: 4:20PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$54.00
Lowest Price Target1
$22.00
Consensus Price Target1
$38.13

Cerevel Therapeutics Hldg Stock (NASDAQ:CERE), Analyst Ratings, Price Targets, Predictions

Cerevel Therapeutics Holdings Inc has a consensus price target of $38.13, established from looking at the 46 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, JP Morgan, and Jefferies on February 16, 2024, December 28, 2023, and December 22, 2023. With an average price target of $45 between Mizuho, JP Morgan, and Jefferies, there's an implied 7.17% upside for Cerevel Therapeutics Holdings Inc from these 3 analyst ratings.

Analyst Trend
1
1
Nov 23
5
Dec 23
1
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Mizuho
JP Morgan
Jefferies
TD Cowen
HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Cerevel Therapeutics Hldg

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/16/2024CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%Mizuho
Graig Suvannavejh
$25 → $45MaintainsNeutralGet Alert
12/28/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%JP Morgan
Jessica Fye
$25 → $45MaintainsNeutralGet Alert
12/22/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%Jefferies
Michael Yee
$40 → $45DowngradeBuy → HoldGet Alert
12/08/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%TD Cowen
Joseph Thome
→ $45DowngradeOutperform → Market PerformGet Alert
12/07/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%HC Wainwright & Co.
Douglas Tsao
$41 → $45DowngradeBuy → NeutralGet Alert
12/07/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%Piper Sandler
David Amsellem
$33 → $45DowngradeOverweight → NeutralGet Alert
12/07/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%Cantor Fitzgerald
Charles Duncan
$38 → $45DowngradeOverweight → NeutralGet Alert
11/20/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-40.46%JP Morgan
Jessica Fye
→ $25Reinstates → NeutralGet Alert
11/02/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-9.5%Morgan Stanley
Matthew Harrison
$42 → $38MaintainsOverweightGet Alert
09/28/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-21.41%Piper Sandler
David Amsellem
→ $33Initiates → OverweightGet Alert
08/07/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-40.46%Mizuho
Graig Suvannavejh
$29 → $25MaintainsNeutralGet Alert
08/03/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.990.02%Morgan Stanley
Matthew Harrison
$46 → $42MaintainsOverweightGet Alert
08/03/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-26.17%B of A Securities
Tazeen Ahmad
$36 → $31DowngradeBuy → NeutralGet Alert
08/03/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-2.36%HC Wainwright & Co.
Douglas Tsao
$45 → $41MaintainsBuyGet Alert
05/23/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-28.55%Goldman Sachs
Madhu Kumar
$31 → $30MaintainsNeutralGet Alert
05/08/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-30.94%Mizuho
Graig Suvannavejh
$26 → $29MaintainsNeutralGet Alert
05/04/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99-28.55%Wells Fargo
Mohit Bansal
→ $30UpgradeEqual-Weight → OverweightGet Alert
04/10/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.99TD Cowen
Joseph Thome
Initiates → OutperformGet Alert
04/03/2023CEREBuy Now
Cerevel Therapeutics Hldg
$41.997.17%HC Wainwright & Co.
Douglas Tsao
→ $45Reiterates → BuyGet Alert

FAQ

Q

What is the target price for Cerevel Therapeutics Hldg (CERE)?

A

The latest price target for Cerevel Therapeutics Hldg (NASDAQ: CERE) was reported by Mizuho on February 16, 2024. The analyst firm set a price target for $45.00 expecting CERE to rise to within 12 months (a possible 7.17% upside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?

A

The latest analyst rating for Cerevel Therapeutics Hldg (NASDAQ: CERE) was provided by Mizuho, and Cerevel Therapeutics Hldg maintained their neutral rating.

Q

When was the last upgrade for Cerevel Therapeutics Hldg (CERE)?

A

The last upgrade for Cerevel Therapeutics Holdings Inc happened on May 4, 2023 when Wells Fargo raised their price target to $30. Wells Fargo previously had an equal-weight for Cerevel Therapeutics Holdings Inc.

Q

When was the last downgrade for Cerevel Therapeutics Hldg (CERE)?

A

The last downgrade for Cerevel Therapeutics Holdings Inc happened on December 22, 2023 when Jefferies changed their price target from $40 to $45 for Cerevel Therapeutics Holdings Inc.

Q

When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cerevel Therapeutics Hldg, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cerevel Therapeutics Hldg was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.

Q

Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?

A

While ratings are subjective and will change, the latest Cerevel Therapeutics Hldg (CERE) rating was a maintained with a price target of $25.00 to $45.00. The current price Cerevel Therapeutics Hldg (CERE) is trading at is $41.99, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch